February 12, 2018 / 9:11 PM / 5 months ago

BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis

Feb 12 (Reuters) - Kadmon Holdings Inc:

* KADMON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF KD025 IN IDIOPATHIC PULMONARY FIBROSIS

* KADMON HOLDINGS INC - ‍KD025 WAS WELL TOLERATED AND DEMONSTRATED CLINICAL BENEFIT​

* KADMON HOLDINGS INC - ‍KD025 HAD NO DRUG-RELATED SERIOUS ADVERSE EVENTS IN PHASE 2 STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below